Press releaseGlobe Newswire
Kamada
KMDA · NASDAQ
$7.85+$0.24 (+3.15%)TodayMarket closed ·
Prev close $7.61
Latest news
- Press releaseGlobe Newswire
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
- Press releaseGlobe Newswire
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
- Press releaseGlobe Newswire
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
- News
Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate
- Press releaseGlobe Newswire
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
- Press releaseGlobe Newswire
Kamada Announces Planned Transition of Chief Financial Officer
- Press releaseGlobe Newswire
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
- Press releaseGlobe Newswire
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
- News
Kamada Q1 2026 Earnings Call: Complete Transcript
- News
Earnings Scheduled For May 13, 2026
- News
Kamada Q1 EPS $0.07 Misses $0.12 Estimate, Sales $45.240M Miss $46.722M Estimate
- Press releaseGlobe Newswire
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
- Press releaseGlobe Newswire
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
- Press releaseGlobe Newswire
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
- News
Earnings Scheduled For March 11, 2026
- Press releaseGlobe Newswire
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
- News
What's Next: Kamada's Earnings Preview
- NewsVandana Singh
Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook
- Press releaseGlobe Newswire
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
- News
An Overview of Kamada's Earnings
- Press releaseGlobe Newswire
Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance
- News
An Overview of Kamada's Earnings
- Press releaseGlobe Newswire
Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
- Press releaseGlobe Newswire
Kamada Declares Special Cash Dividend of $0.20 Per Share
- News
What's Next: Kamada's Earnings Preview
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.